Pfizer Inc
PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3056% above fair value
$30.52+0.57 (+1.90%)
Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%
Pfizer Octagam / Panzyga (immunoglobulin portfolio) by Year
Octagam / Panzyga (immunoglobulin portfolio) — Worldwide reported YoY (%) (%)
Pfizer Octagam / Panzyga (immunoglobulin portfolio): -18.0% in FY2025.
Latest, FY2025
-18.0%
Period ended Dec 31, 2025
Change on a year earlier
–
History
3 years
Since FY2022
Sources
3
Documents cited below
Where the FY2025 figure comes from
“|| Octagam | 418 | 509 | (18%) | (18%) | 418 | 509 | (18%) | — | — | — | —”
Source: Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
Reported in Form 8-K Revenue Tables.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Octagam / Panzyga (immunoglobulin portfolio) — Worldwide reported YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | -18.0% | – | Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗ |
| FY2023 | Dec 31, 2023 | 19.0% | +5.0 pts | Form 8-K (Earnings / Guidance Release) (pfe-12312023xex99.htm, filed 2024-01-30) ↗ |
| FY2022 | Dec 31, 2022 | 14.0% | – | Form 8-K (Earnings / Guidance Release) (pfe-12312022xex99.htm, filed 2023-01-31) ↗ |
Cite this data
StockData. (2026). Pfizer Octagam / Panzyga (immunoglobulin portfolio) (%), annual FY2022–FY2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/octagam-yoy-ww
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.